Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MedicureTSXV:MPH +29.25%65 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus rates TSXV:MPH with a GF Score™ of 65/100 and a GF Value™ of C$1.53 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 810 Drug Manufacturers companies, Medicure ranks worse than 123456.67% on this metric.
During the past 12 months, Medicure's average EBITDA Per Share Growth Rate was -521.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Medicure was 66.50% per year. The lowest was -58.80% per year. And the median was -9.35% per year.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Medicure 3-Year EBITDA Growth Rate Related Terms
TSXV:MPH vs ZTS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Medicure's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medicure 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Medicure's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Medicure's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 0.00% mean?
Medicure (TSXV:MPH) has a 3-Year EBITDA Growth Rate of 0.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medicure and its competitors. According to the industry distribution chart, Medicure ranks #999999 out of 810 companies in the Drug Manufacturers industry.
Is Medicure's 3-Year EBITDA Growth Rate too high?
Medicure's current 3-Year EBITDA Growth Rate is 0.00%. Based on the distribution chart, Medicure ranks #999999 out of 810 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Medicure has a GF Score™ of 65/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medicure's 3-Year EBITDA Growth Rate compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Medicure ranks #999999 out of 810 companies for 3-Year EBITDA Growth Rate. This places Medicure in the lower half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Medicure and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medicure's current 3-Year EBITDA Growth Rate is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medicure stock overvalued right now?
Based on GuruFocus' analysis, Medicure (TSXV:MPH) is currently considered Modestly Overvalued. The stock's GF Value™ is C$1.53, compared to a current price of C$1.90 — trading 24.2% above its estimated fair value. The current 3-Year EBITDA Growth Rate is 0.00%. Medicure's overall GF Score™ is 65/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Medicure (TSXV:MPH), the current 3-Year EBITDA Growth Rate is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medicure (TSXV:MPH) Overvalued in 2026?
Based on GuruFocus' analysis, Medicure stock appears to be overvalued.
The current stock price of C$1.90 is trading 24.2% above its estimated GF Value™ of C$1.53.
GuruFocus considers Medicure to be Modestly Overvalued.
Key valuation signals for TSXV:MPH:
3-Year EBITDA Growth Rate: 0.00%
GF Value™: C$1.53 vs. price of C$1.90 (24.2% above fair value)
No single metric tells the full story. See the TSXV:MPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medicure Inc is focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market and sales to the Retail Public of pharmaceutical products. The Company's present focus is the sale and marketing of its cardiovascular products, AGGRASTAT, ZYPITAMAG, and increasing its e-commerce and mail order pharmaceutical business. The Company operates under two segments: the marketing and distribution of commercial products and the operation of a retail and mail order pharmacy. It generates the majority of its revenue from the Retail and Mail Order Pharmacy segment.
65GF Score
Get the complete analysis for TSXV:MPH
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSXV:MPH has been successfully added to your 
